These findings are supported by studies in the EAE model of MS, which showed that PPAR and LXR-deficient mice presented an exacerbated clinical phenotype, higher cytokine production, and more severe demyelination compared to wild-type or untreated animals [107–110]. This evidence concerns the gene PPARA and myeloid sarcoma.